F. Wang
3 Papers
F. Wang is an academic researcher. The author has contributed to research in topics: Pharmacodynamics & Pharmacokinetics. The author has co-authored 2 publications.
Chat about Author
Papers
Multiple topological nodal structure in LaSb2 with large linear magnetoresistance
Yinan Qiao,Z Tao,F. Wang,Huaiqiang Wang,Z.T.Y. Liu,Soohyun Cho,F. Zhang,Q. Meng,Wei Xia,Y. C. Yang,Ziwen Huang,J. S. Liu,Z. Liu,Z W Zhu,Suyan Qiao,Y F Guo,Haijun Zhang,Dawei Shen +17 more
- 22 Aug 2022
TL;DR: In this article , the authors proposed a method to solve the problem of high-dimensional topological physics by using a topological model and showed that the model can be used for topological particle physics.
2
29P A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
Y. Fan,Y. Xu,Z. Huang,Wei-xiang Hong,Lei Gong,K. Chen,Jun Qin,Fajun Xie,F. Wang,X. Tian,X. N. Meng,W. Feng,L Li,Xinmei Kang +13 more
1
[Empagliflozin alleviates cardiac microvascular ischemia/reperfusion injury by maintaining myocardial mitochondrial homeostasis].
C. Song,Z. Huang,W. Chen,F. Wang,L. Cai,F. Zhao,Y. Zhao +6 more
TL;DR: EMPA can alleviate myocardial I/R injury by maintaining mitochondrial homeostasis to protect the microvascular system by reducing mitochondrial DNA replication and transcription and lowering the expression levels of Cox-Ⅰ and Cox- Ⅱ in HCAECs.
1